全文获取类型
收费全文 | 9190篇 |
免费 | 930篇 |
国内免费 | 28篇 |
专业分类
耳鼻咽喉 | 67篇 |
儿科学 | 216篇 |
妇产科学 | 217篇 |
基础医学 | 1438篇 |
口腔科学 | 174篇 |
临床医学 | 1210篇 |
内科学 | 1743篇 |
皮肤病学 | 197篇 |
神经病学 | 604篇 |
特种医学 | 560篇 |
外科学 | 1185篇 |
综合类 | 156篇 |
一般理论 | 6篇 |
预防医学 | 901篇 |
眼科学 | 125篇 |
药学 | 574篇 |
中国医学 | 8篇 |
肿瘤学 | 767篇 |
出版年
2021年 | 119篇 |
2020年 | 80篇 |
2019年 | 146篇 |
2018年 | 152篇 |
2017年 | 124篇 |
2016年 | 125篇 |
2015年 | 137篇 |
2014年 | 193篇 |
2013年 | 303篇 |
2012年 | 421篇 |
2011年 | 453篇 |
2010年 | 259篇 |
2009年 | 270篇 |
2008年 | 414篇 |
2007年 | 440篇 |
2006年 | 405篇 |
2005年 | 410篇 |
2004年 | 400篇 |
2003年 | 370篇 |
2002年 | 321篇 |
2001年 | 265篇 |
2000年 | 297篇 |
1999年 | 267篇 |
1998年 | 115篇 |
1997年 | 142篇 |
1996年 | 122篇 |
1995年 | 101篇 |
1994年 | 98篇 |
1993年 | 90篇 |
1992年 | 213篇 |
1991年 | 230篇 |
1990年 | 180篇 |
1989年 | 183篇 |
1988年 | 187篇 |
1987年 | 149篇 |
1986年 | 169篇 |
1985年 | 153篇 |
1984年 | 117篇 |
1983年 | 101篇 |
1982年 | 72篇 |
1981年 | 82篇 |
1979年 | 81篇 |
1978年 | 91篇 |
1977年 | 81篇 |
1976年 | 82篇 |
1975年 | 75篇 |
1974年 | 92篇 |
1973年 | 80篇 |
1972年 | 68篇 |
1971年 | 66篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
31.
32.
Appraising Public Medical Services 总被引:5,自引:0,他引:5
33.
34.
35.
Picotamide inhibition of excess in vitro thromboxane B2 release by colorectal mucosa in inflammatory bowel disease. 总被引:1,自引:0,他引:1
Collins CE Benson MJ Burnham WR Rampton DS 《Alimentary pharmacology & therapeutics》1996,10(3):315-320
BACKGROUND: Inflammatory bowel disease is associated with increased mucosal release of eicosanoids. Among these, thromboxane A2 has been proposed as a possible inflammatory mediator; its suppression may be a useful therapeutic option. METHODS: Using a tissue incubation technique, we compared release of immunoreactive thromboxane B2 by colonic biopsies from patients with ulcerative colitis, Crohn's disease and controls, and assessed the inhibitory effect of picotamide, a thromboxane synthesis inhibitor-receptor antagonist, which has been widely used in Italy for management of ischaemic heart and cerebrovascular disease. RESULTS: Increased amounts of thromboxane B2 were released from biopsies from patients with active ulcerative colitis (median 238 pg/20 min/mg wet weight (interquartile range 147- 325), n = 12) and active Crohn's disease (252 (174-450), 6) compared with those from patients with quiescent ulcerative colitis (95 (61- 140), 12) or Crohn's disease (105 (57-201), 13), or controls (136 (64- 206), 8). Incubation with picotamide at concentrations between 100 microM and 1 mM reduced thromboxane B2 release (IC50 890 microM). CONCLUSION: Since increased thromboxane A2 production may have pathogenetic importance, thromboxane synthesis inhibitor-receptor antagonists such as picotamide merit therapeutic trial in the management of inflammatory bowel disease. 相似文献
36.
Reed Jon A.; Nador Roland G.; Spaulding David; Tani Yoichi; Cesarman Ethel; Knowles Daniel M. 《Blood》1998,91(10):3825-3832
37.
Anderson RA; Evans LW; Irvine DS; McIntyre MA; Groome NP; Riley SC 《Human reproduction (Oxford, England)》1998,13(12):3319-3325
Follistatin is a binding protein for the activin and inhibin family of
hormones, regulating their biological activity. In the male reproductive
tract, the interaction of these factors is likely to be involved in the
regulation of the proliferation of several cell types. We have investigated
the presence of follistatin and activin A in seminal plasma using specific
immunoassays and have localized follistatin and activin/inhibin subunits in
the adult human testis, prostate and seminal vesicle to establish their
likely sources. High concentrations of immunoreactive follistatin were
present in seminal plasma in normal men (mean 97.9 ng/ml; 1.43 ng/ml in
peripheral plasma) and were similar in men with oligo/azoospermia and
following vasectomy. Follistatin immunoreactivity was localized to both
Leydig and Sertoli cells of the testis, and to epithelial cells of the
prostate gland and seminal vesicle, which are likely to be the predominant
sources of the hormone in seminal plasma. Activin A was also present in
seminal plasma in normal men but was undetectable following vasectomy, thus
deriving from the testis. Consistent with this finding, the betaA-subunit
was immunolocalized in Sertoli and Leydig cells but was not present in
seminal vesicle or prostate gland. The functional significance of the high
concentrations of follistatin secreted into seminal plasma by the prostate
gland and/or seminal vesicle is uncertain, but they may regulate the
biological activity of testis-derived activin A and inhibin B.
相似文献
38.
39.
W P Vaughan J D Dennison E C Reed L Klassen T R McGuire W G Sanger P P Kumar P I Warkentin B G Gordon P J Bierman 《Bone marrow transplantation》1991,8(6):489-495
Twenty-four patients between the ages of 8 and 48 years (median 27.5) with high-risk for relapse hematologic malignancy received a marrow transplant from an HLA and MLC compatible sibling donor after chemotherapy with busulfan, 4 mg/kg/day for 4 days by mouth, cyclophosphamide 60 mg/kg/day i.v. for 2 days, and etoposide 60 mg/kg i.v. over 4 h on the first day of cyclophosphamide treatment (BU/CY/VP). Toxicity consisted of mucositis, skin rash, and nausea and vomiting in all patients, transient fever thought to be due to etoposide administration in 16/24 (67%) patients, and clinical veno-occlusive disease (VOD) of the liver in 4/24 (17%). There were nine deaths from causes other than recurrent disease in the first 100 days after transplant and two deaths after day 100, a total transplant mortality of 11/24 (46%). Three patients relapsed, but 10/24 (40%) remain alive and disease free 26-182 weeks (median 60 weeks) from transplant. These results compare favorably with results in a group of 12 similar risk patients treated with total body irradiation (TBI) containing regimens during an overlapping time period. Six of the TBI patients have had persistent or recurrent disease and only two (17%) are currently alive and disease free. The probability of disease persistence or relapse is 67% in the TBI group and 20% in the BU/CY/VP group (p less than 0.02). 相似文献
40.
It is estimated that 1.7% of orthotopic liver transplant recipients will develop abdominal aortic aneurysms (AAAs) after transplantation. It has been observed that these aneurysms expand faster in transplant recipients; therefore, aggressive surveillance for AAAs in transplant recipients is required. Endovascular aneurysm repair is rapidly becoming the standard of care, especially in patients with previous abdominal surgery and other significant comorbidities. This article describes our experience with AAAs in orthotopic liver transplant recipients treated successfully by endovascular stent graft repair. 相似文献